global top 10 biopharmaceutical company × Ovation.io
Ovation.io announced the launch of a new dataset of whole genome sequences and longitudinal clinical records for patients treated with GLP-1 drugs. [73] A non-disclosed global top 10 biopharmaceutical company became the first customer, committing to a three-year data license to use the data for research in metabolic diseases. [73] The price of the license was not disclosed.
The asset
A three-year data license to a research dataset combining whole genome sequencing (WGS) data with longitudinal clinical records of patients treated with GLP-1 receptor agonists. [73]
- 9k patient records by end of 2025
The record
- Seller status
- Going concern
- Sector
- Clinical and genomic data
- Modalities
- genomic data, clinical data
- Jurisdiction
- US
- Personal data
- The dataset consists of de-identified, consented, and tokenized samples linked to rich, longitudinal phenotypic data. [74]
What it means if you hold data
This deal exemplifies the high demand for specialized, multi-modal datasets in hot therapeutic areas like GLP-1s. It shows that even without a named buyer, the announcement of a significant data licensing deal by a major pharma player validates the commercial value of curated, real-world genomic and clinical data. [73]